Hims & Hers Health, Inc. (HIMS) Stock Performance and Citigroup's Rating

• Citigroup maintains a "Sell" rating for Hims & Hers Health, Inc. (NYSE:HIMS) despite a 38.6% surge in stock price.
• The stock's performance significantly outpaces both the Zacks S&P 500 composite and the Zacks Medical Info Systems industry.
• HIMS showcases volatility with a current stock price of $56.77 and a market capitalization of approximately $12.23 billion.

Hims & Hers Health, Inc. (NYSE:HIMS) is a telehealth company that provides a range of health and wellness products and services. The company focuses on offering accessible healthcare solutions through its online platform, catering to both men and women. HIMS operates in the competitive telehealth industry, where it faces competition from other digital health companies.

On June 2, 2025, Citigroup maintained its "Sell" rating for HIMS, with the stock priced at approximately $56.76 at the time. Despite this rating, HIMS has seen a remarkable surge in its stock price, increasing by 38.6% over the past month. This performance significantly outpaces the Zacks S&P 500 composite's 6.1% rise and the 16.9% gain in the Zacks Medical Info Systems industry.

The current stock price of HIMS is $56.77, reflecting a slight change of $0.21, or 0.37%. The stock has traded between $55.68 and $58.77 today, showcasing some volatility. Over the past year, HIMS has experienced a high of $72.98 and a low of $13.47, indicating a wide range of price movements.

HIMS has a market capitalization of approximately $12.23 billion, highlighting its significant presence in the telehealth sector. Today's trading volume for HIMS is 34,842,297 shares, suggesting active investor interest. As highlighted by Benzinga, the article "Check Out What Whales Are Doing With HIMS" may provide further insights into the stock's dynamics.

While media reports and rumors can cause immediate price fluctuations, fundamental factors like earnings estimate revisions are crucial for long-term investment decisions. Investors should consider these elements when evaluating HIMS's future trajectory in the telehealth industry.